Business
View all stories with this category.
-
OpinionWill Novartis's data manipulation damage relations with regulators?
Trust between the two has been compromised
-
NewsData manipulation casts shadows on Novartis gene therapy
Manufacturing problems with other new medicines highlight difficulty of developing advanced treatments
-
OpinionHas x-ray had its day?
Will the giant of structure determination be toppled by blasts from electron beams?
-
OpinionAre new drugs better than existing ones?
Should companies be made to change the way they run clinical trials?
-
BusinessEnhancing solvents' sustainability
Increased recycling and replacing toxic solvents with greener alternatives will reduce environmental impact
-
BusinessPfizer’s Upjohn to merge with Mylan
Deal combines Pfizer’s off-patent drug portfolio with Mylan’s generics
-
BusinessUS ditches chlorpyrifos ban for food crops
Environmental Protection Agency says evidence of harm from food residues is insufficient
-
BusinessHexagonFab cracks nanomanufacturing for pocket diagnostics
HexagonFab’s founders say their graphene-based sensors are set to become the lab tests that don’t need a physical lab
-
BusinessUS judges slash damages in glyphosate cancer lawsuits
While upholding rulings linking the herbicide to cancer, judges have cut Bayer-Monsanto’s fines from billions to tens of millions of dollars
-
BusinessCurbing industry’s carbon emissions
Replacing fossil-fuelled furnaces with renewable electrical heating and cutting carbon from some heavy industries could make a serious dent in climate targets